Resolution Therapeutics
June 18, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution’s initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis.
Company HQ City:
Edinburgh
Company HQ Country:
United Kingdom
Year Founded:
2017
Lead Product in Development:
RTX001 is an engineered autologous macrophage cell therapy designed to deliver increased anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease. The product candidate is engineered using a unique combination of therapeutic genes known to be expressed in macrophages to enhance the inherent regenerative properties of the modality for superior efficacy and durability. RTX001 is being evaluated in the Phase 1/2 EMERALD study in end-stage liver disease measuring clinical events as the primary efficacy endpoint. The EMERALD started recruiting patients in October 2024 in the U.K. It is expected to start recruiting patients in Spain in the second quarter of 2025.
CEO
Amir Hefni, CEO
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
Additional preclinical data for RTX001 in additional indications anticipated 3Q25. RTX001 Phase I/II interim readout anticipated in 1Q26.
What is your next catalyst (value inflection) update?
3Q25
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}